Geburtshilfe Frauenheilkd 2016; 76(12): 1310-1317
DOI: 10.1055/s-0042-116494
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Herpes Genitalis: Diagnosis, Treatment and Prevention

Diagnostik des Herpes genitalis, einschließlich antiviraler Therapie und prophylaktischer Möglichkeiten
A. Sauerbrei
Institut für Virologie und Antivirale Therapie, Konsiliarlabor für HSV und VZV, Universitätsklinikum Jena, Jena, Germany
› Author Affiliations
Further Information

Publication History

received 23 June 2016
revised 15 August 2016

accepted 01 September 2016

Publication Date:
18 October 2016 (online)


Herpes genitalis is caused by the herpes simplex virus type 1 or type 2 and can manifest as primary or recurrent infection. It is one of the most common sexually transmitted infections and due to associated physical and psychological morbidity it constitutes a considerable, often underestimated medical problem. In addition to providing the reader with basic knowledge of the pathogen and clinical presentation of herpes genitalis, this review article discusses important aspects of the laboratory diagnostics, antiviral therapy and prophylaxis. The article is aimed at all health-care workers managing patients with herpes genitalis and attempts to improve the often suboptimal counselling, targeted use of laboratory diagnostics, treatment and preventive measures provided to patients.


Der Herpes genitalis wird durch Herpes-simplex-Virus Typ 1 oder Typ 2 hervorgerufen und kann sich als primäre und rekurrierende Infektion manifestieren. Die Erkrankung gehört zu den häufigsten sexuell erworbenen Infektionskrankheiten und stellt aufgrund ihrer physikalischen und psychosozialen Morbidität ein erhebliches und oft unterschätztes medizinisches Problem dar. In der vorliegenden Übersichtsarbeit werden neben medizinischen Grundkenntnissen zum Erreger des Herpes genitalis und der Erkrankung wesentliche Aspekte der Labordiagnostik, einschließlich antivirale Therapie und prophylaktische Möglichkeiten vermittelt. Der Beitrag wendet sich an alle Mitarbeiter im Gesundheitsdienst, die Patienten mit Herpes genitalis betreuen, und zielt darauf ab, die häufig unzureichende Beratung sowie Maßnahmen bez. einer gezielten Diagnostik, Therapie und Prävention bei den betroffenen Patienten zu verbessern.

Supporting Information

  • References

  • 1 King AM, Adams MJ, Carstens EB, Lefcowitz EJ Hrsg. Virus Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses. San Diego, CA: Elsevier Academic Press; 2012: 99-124
  • 2 Bergström T, Trybala E. Antigenic differences between HSV-1 and HSV-2 glycoproteins and their importance for type-specific serology. Intervirology 1996; 39: 176-184
  • 3 Scheper T, Saschenbrecker S, Steinhagen K et al. The glycoproteins C and G are equivalent target antigens for the determination of herpes simplex virus type 1-specific antibodies. J Virol Methods 2010; 166: 42-47
  • 4 Sauerbrei A, Schmitt S, Scheper T et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. Euro Surveill 2011; pii:20005
  • 5 Wutzler P, Doerr HW, Färber I et al. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. J Med Virol 2000; 61: 201-207
  • 6 Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186 (Suppl. 01) S3-S28
  • 7 Langenberg AG, Corey L, Ashley RL et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chirion HSV Vaccine Study Group. N Engl J Med 1999; 341: 1432-1438
  • 8 Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30: 797-800
  • 9 Peña KC, Adelson ME, Mordechai E et al. Genital herpes simplex virus type 1 in women: detection in cervicovaginal specimens from gynecological practices in the United States. J Clin Microbiol 2010; 48: 150-153
  • 10 Freeman EE, Weiss HA, Glynn JR et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83
  • 11 Bernstein DI, Bellamy AR, Hook 3rd EW et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56: 344-351
  • 12 Corey L, Adams HG, Brown ZA et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98: 958-972
  • 13 Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. Science 1971; 173: 843-845
  • 14 Perna JJ, Mannix ML, Rooney JF et al. Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model. J Am Acad Dermatol 1987; 17: 473-478
  • 15 Rand KH, Hoon EF, Massey JK et al. Daily stress and recurrence of genital herpes. Arch Intern Med 1990; 150: 1889-1893
  • 16 Bennedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121: 847-854
  • 17 Engelberg R, Carrell D, Krantz E et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30: 174-177
  • 18 Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-2137
  • 19 Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357: 1513-1518
  • 20 Catotti DN, Clarke P, Catoe KE. Herpes revisited. Sex Transm Dis 1993; 20: 77-80
  • 21 Hofstetter AM, Rosenthal L, Stanberry LR. Current thinking on herpes genitalis. Curr Opin Infect Dis 2014; 27: 75-83
  • 22 Sauerbrei A. Herpes-simplex-Virusinfektionen. In: DVV, GfV, Hrsg. S2k-Leitlinie Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. Berlin, Heidelberg: Springer; 2014: 145-157
  • 23 Anzivino E, Fioriti D, Mischitelli M et al. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. Virol J 2009; 6: 40
  • 24 Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy – current concepts of prevention, diagnosis and therapy. Part 1: Herpes simplex virus infections. Med Microbiol Immunol 2007; 196: 89-94
  • 25 Rudnick CM, Hoekzema GS. Neonatal herpes simplex virus infections. Am Fam Physician 2002; 6: 1138-1142
  • 26 Corey L, Wald A. Maternal and neonatal HSV infections. N Engl J Med 2009; 361: 1376-1385
  • 27 Kohl S. Neonatal herpes simplex virus infection. Clin Perinatol 1997; 24: 129-150
  • 28 Deutsche STI-Gesellschaft. S1-Leitlinie STI/STD – Beratung, Diagnostik und Therapie. Online: last access: 22.06.2016
  • 29 Sauerbrei A, Eichhorn U, Hottenrott G et al. Virological diagnosis of herpes simplex encephalitis. J Clin Virol 2000; 17: 31-36
  • 30 LeGoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J 2014; 11: 83
  • 31 Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64: 1-137
  • 32 Patel R, Alderson S, Geretti A et al. European guideline for the management of genital herpes, 2010. Int J STD AIDS 2011; 22: 1-10
  • 33 Wald A, Huang ML, Carrell D et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surface: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188: 1345-1351
  • 34 Sauerbrei A, Eichhorn U, Schacke M et al. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31-36
  • 35 Wagenlehner FM, Brockmeyer NH, Discher T et al. The presentation, diagnosis and treatment of sexually transmitted infections. Dtsch Arztebl Int 2016; 113: 11-23
  • 36 Swiss Herpes Management Forum. Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. Swiss Med Wkly 2004; 134: 205-214
  • 37 Brown ZA. Case study: type-specific HSV serology and the correct diagnosis of first-episode genital herpes during pregnancy. Herpes 2002; 9: 24-26
  • 38 Zahariadis G, Severini A. Evaluation of a novel serology algorithm to detect herpes simplex virus 1 or 2 antibodies. Sex Transm Dis 2010; 37: 696-699
  • 39 Bentley J, Neubauer A, Sauerbrei A. Value of herpes simplex virus type-specific serology: a case report. J Clin Virol 2012; 54: 269-271
  • 40 Hashido M, Inouye S, Kawana T. Differentiation of primary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay. J Clin Microbiol 1997; 35: 1766-1768
  • 41 Liermann K, Schäfler A, Henke A et al. Evaluation of commercial HSV IgG and IgM enzyme immunoassays. J Virol Methods 2014; 199: 29-34
  • 42 Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. Section 5 – Management and treatment of specific infections. Genital herpes simplex virus (HSV) infections. Online: last access: 11.08.2016
  • 43 German STI-Society. STI-Treatment Pocket Guide. Online: last access: 22.06.2016
  • 44 De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother 2013; 23: 93-101
  • 45 Le Cleach L, Trinquart L, Do G et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients (review). Cochrane Database Syst Rev 2014; (8) CD009036
  • 46 Hollier LM, Wendel D. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal herpes. Cochrane Database Syst Rev 2008; (1) CD004946
  • 47 Stone KM, Reiff-Eldridge R, White AD et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res Clin Mol Teratol 2004; 70: 201-207
  • 48 Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-866
  • 49 Kang SH, Chua-Gocheco A, Einarson A. Safety of antiviral medication for the treatment of herpes during pregnancy. Can Fam Physician 2011; 57: 427-428
  • 50 Danve-Szatanek C, Aymard M, Thouvenot D et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42: 242-249
  • 51 Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 76-80
  • 52 Patel R, Green J, Clarke E et al. 2014 UK national guideline for the management of anogenital herpes. Int J STD AIDS 2015; 26: 763-776
  • 53 Wald A, Corey L, Timmler B et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 2014; 370: 201-210
  • 54 Collot M, Rouard C, Brunet C et al. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies. Antiviral Res 2016; 128: 1-6
  • 55 Balfour jr. HH, Benson C, Braun J et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7: 254-260
  • 56 Sauerbrei A, Bohn-Wippert K, Kaspar M et al. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and 2. J Antimicrob Chemother 2016; 71: 6-16
  • 57 Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26: 29-37
  • 58 Schmidt S, Bohn-Wippert K, Zell R et al. Sequence analysis of herpes simplex virus type 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973–2014 finds novel mutations which may be relevant for development of antiviral resistance. Antimicrob Agents Chemother 2015; 59: 4938-4945
  • 59 Safrin S, Crumpacker C, Chatis P et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551-555
  • 60 Awasthi S, Friedman M. Status of prophylactic and therapeutic genital herpes vaccines. Curr Opin Virol 2014; 6: 6-12
  • 61 Odegard JM, Flynn PA, Campbell DJ et al. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 2016; 34: 101-109
  • 62 Straus SE, Corey L, Burke RL et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343: 1460-1463
  • 63 Straus SE, Wald A, Kost RK et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotein D and B. results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176: 1129-1134
  • 64 Casanova G, Cancela R, Alonzo L et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002; 70: 235-239
  • 65 deBruyn G, Vargas-Cortez M, Warren T et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24: 914-920
  • 66 Halford WP, Geltz J, Messer RJ et al. Antibodies are required for complete vaccine-induced protection against herpes simplex virus 2. PLoS One 2015; 10: e0145228
  • 67 Stanaway JD, Wald A, Martin ET et al. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis 2012; 39: 388-393
  • 68 Gottlieb SL, Douglas jr. JM, Foster M et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counselling. J Infect Dis 2004; 15: 1059-1067
  • 69 Abdool Karim SS, Abdool Karim Q, Kharsany AB et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med 2015; 373: 530-539
  • 70 Bender Ignacio RA, Perti T, Magaret AS et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. J Infect Dis 2015; 212: 1949-1956
  • 71 Price CF, Tyssen D, Sonza S et al. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 2011; 6: e24095